<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425279</url>
  </required_header>
  <id_info>
    <org_study_id>BA3011-001</org_study_id>
    <nct_id>NCT03425279</nct_id>
  </id_info>
  <brief_title>Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma</brief_title>
  <official_title>A Phase 1/ 2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-AXL-ADC, Alone and in Combination With a PD-1 Inhibitor in Adult Patients With Advanced Solid Tumors (Phase 1) and Adult and Adolescent Patients With Advanced, Refractory Sarcoma (Phase 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAtla, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAtla, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety,&#xD;
      tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active&#xD;
      biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced&#xD;
      solid tumors in Phase 1 and BA3011 alone and in combination with a PD-1 inhibitor in Phase 2.&#xD;
&#xD;
      Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct&#xD;
      2019) and a dose expansion phase (still enrolling).&#xD;
&#xD;
      Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12&#xD;
      and over.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assess dose limiting toxicity as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assess maximum tolerated dose as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 and 2: Safety Profile</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Frequency and severity of AEs and/or SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Plasma concentrations of ADC, total antibody and MMAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Pharmacokinetics</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients who achieve a confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Immunogenicity</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The number and percentage of patients who develop detectable anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Duration of response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Best overall response (OR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Disease control rate (DCR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Time to response (TTR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of investigational product until the first documentation of OR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Overall survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the first dose of BA3011 treatment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Tumor size</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Percent change from baseline in tumor size</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <condition>Sarcoma, Ewing</condition>
  <condition>Osteosarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Liposarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Bone Sarcoma</condition>
  <condition>Refractory Sarcoma</condition>
  <arm_group>
    <arm_group_label>BA3011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: BA3011 in combination with PD-1 inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAB-AXL-ADC</intervention_name>
    <description>Conditionally active biologic anti-AXL antibody drug conjugate</description>
    <arm_group_label>BA3011</arm_group_label>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>PD-1 inhibitor</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have measurable disease.&#xD;
&#xD;
          -  Age ≥ 12 years (Phase 2)&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy of at least three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients must not have clinically significant cardiac disease.&#xD;
&#xD;
          -  Patients must not have known non-controlled CNS metastasis.&#xD;
&#xD;
          -  Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as&#xD;
             wellas known or suspected allergy or intolerance to any agent given during this study.&#xD;
&#xD;
          -  Patients must not have had major surgery within 4 weeks before first BA3011&#xD;
             administration.&#xD;
&#xD;
          -  Patients must not have had prior therapy with a conjugated or unconjugated auristatin&#xD;
             derivative/vinca-binding site targeting payload.&#xD;
&#xD;
          -  Patients must not have known human immunodeficiency virus (HIV) infection, active&#xD;
             hepatitis B and/or hepatitis C.&#xD;
&#xD;
          -  Patients must not be women who are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hazel Buncab</last_name>
    <phone>858-263-1598</phone>
    <phone_ext>8582631598</phone_ext>
    <email>hbuncab@bioatla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Hwan Lee</last_name>
    <phone>8582867702</phone>
    <email>jlee@bioatla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Huynh</last_name>
      <phone>520-694-1231</phone>
      <email>jhhyuynh@arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Hodges</last_name>
      <phone>520-694-9058</phone>
      <email>mhodges@arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pavani Chalasani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Lee</last_name>
      <phone>323-865-0455</phone>
      <email>Cristina.Lee@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tower Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Menendez</last_name>
      <phone>310-231-2184</phone>
      <email>rmenendez@theangelesclinic.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Ford, PA-C</last_name>
      <phone>310-285-7268</phone>
      <email>Linda.ford@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zack Morgan</last_name>
      <phone>303-724-6429</phone>
      <email>Zackry.morgan@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea Mason</last_name>
      <phone>720-848-0289</phone>
      <email>chelsea.mason@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Breelyn Wilky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Health One</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Hall</last_name>
      <phone>720-754-2659</phone>
      <email>Susan.Hall3@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Falchook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Liew</last_name>
      <phone>202-476-6755</phone>
      <email>aliew@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>AeRang Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milijana Ugrenovic-Petrovic</last_name>
      <email>Milijana.Ugrenovic-Petrovic@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Soha Riad</last_name>
      <email>Soha.Riad@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mihaela Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylee Fleig</last_name>
      <phone>502-629-3681</phone>
      <email>Kylee.Fleig@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Jaspreet Grewal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swathi Balaji</last_name>
      <phone>212-304-5548</phone>
      <email>sb4461@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Bryant</last_name>
      <phone>212-342-9004</phone>
      <email>mb4695@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Ingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Ragazzo</last_name>
      <phone>929-321-7075</phone>
      <email>ragazzos@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kash Haque</last_name>
      <email>haquek1@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bill M. Tap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley C Fansler, RN</last_name>
      <phone>336-713-3539</phone>
      <email>arcarrol@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Savage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Logue</last_name>
      <phone>216-286-1090</phone>
      <email>Kyle.Logue@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Ankit Mangla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zach Godwin</last_name>
      <phone>503-418-9324</phone>
      <email>godwinz@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Lara Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Burris, MD</last_name>
      <email>Howard.Burris@SarahCannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Costin</last_name>
      <phone>615-329-7274</phone>
      <email>Jamie.Costin@SarahCannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Burris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon</last_name>
      <phone>713-792-8927</phone>
      <email>JRodon@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Diep T Tran</last_name>
      <phone>713-792-8927</phone>
      <email>dttran3@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Rodon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sharry</last_name>
      <phone>801-585-3453</phone>
      <email>susan.sharry@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Leary</last_name>
      <phone>801-213-8429</phone>
      <email>Ashley.leary@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anna Chalmers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>late stage</keyword>
  <keyword>stage 3</keyword>
  <keyword>stage 4</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

